{"transactions":[{"id":4626033,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-09-24T20:10:50.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":3927,"price":58.9261,"value":231402.7947,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":270401,"source":{"system":"sec-edgar","filing":"0001814238-26-000017","document":"wk-form4_1790280647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000017/wk-form4_1790280647.xml","form_type":"4"}},{"id":4626032,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-09-24T20:10:50.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":96073,"price":58.5148,"value":5621692.3804,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":274328,"source":{"system":"sec-edgar","filing":"0001814238-26-000017","document":"wk-form4_1790280647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000017/wk-form4_1790280647.xml","form_type":"4"}},{"id":681501,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-19T20:20:53.000Z","date":"2026-08-19","kind":"gift","planned":true,"acquired":false,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person made a charitable gift of Class A Ordinary Shares to Lehigh University."}],"balance_after":23200,"source":{"system":"sec-edgar","filing":"0001814238-26-000015","document":"wk-form4_1787170851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000015/wk-form4_1787170851.xml","form_type":"4"}},{"id":681500,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-19T20:20:53.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":100000,"price":59.9725,"value":5997250.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported sales were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.68 to $60.42 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":370401,"source":{"system":"sec-edgar","filing":"0001814238-26-000015","document":"wk-form4_1787170851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000015/wk-form4_1787170851.xml","form_type":"4"}},{"id":693131,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:12:26.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":11002,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":470401,"source":{"system":"sec-edgar","filing":"0001814238-26-000013","document":"wk-form4_1786137144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000013/wk-form4_1786137144.xml","form_type":"4"}},{"id":718169,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":600,"price":57.09,"value":34254.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.11 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718168,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":29400,"price":56.4423,"value":1659403.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $56.95 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40600,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718167,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":2554,"price":57.1031,"value":145841.3174,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.06 to $57.22 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":459399,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":718166,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:08:32.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":97446,"price":56.5028,"value":5505971.8488,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":461953,"source":{"system":"sec-edgar","filing":"0001814238-26-000011","document":"wk-form4_1783022904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000011/wk-form4_1783022904.xml","form_type":"4"}},{"id":726431,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:11:53.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":117592,"price":54.4746,"value":6405777.1632,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":559399,"source":{"system":"sec-edgar","filing":"0001814238-26-000009","document":"wk-form4_1782421910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000009/wk-form4_1782421910.xml","form_type":"4"}},{"id":726430,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chairman, Partnering"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:11:53.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":32408,"price":54.107,"value":1753499.656,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":676991,"source":{"system":"sec-edgar","filing":"0001814238-26-000009","document":"wk-form4_1782421910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000009/wk-form4_1782421910.xml","form_type":"4"}},{"id":786943,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:12:19.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":24263,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":709399,"source":{"system":"sec-edgar","filing":"0001814238-26-000007","document":"wk-form4_1778274737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000007/wk-form4_1778274737.xml","form_type":"4"}},{"id":804525,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:05:01.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000119312526164226/ownership.xml","form_type":"4"}},{"id":853651,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-09T20:49:21.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":24937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date."}],"balance_after":24937,"derivative":{"exercise_price":38.85,"expiration_date":"2036-03-04","underlying":"Class A Common Stock","underlying_shares":24937},"source":{"system":"sec-edgar","filing":"0001814238-26-000005","document":"form4-03092026_080317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000005/form4-03092026_080317.xml","form_type":"4"}},{"id":905335,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:02:51.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":26626,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":685136,"source":{"system":"sec-edgar","filing":"0001814238-26-000002","document":"wk-form4_1771016568.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000002/wk-form4_1771016568.xml","form_type":"4"}},{"id":1004951,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-07T21:18:10.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":6168,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":658510,"source":{"system":"sec-edgar","filing":"0001814238-25-000003","document":"wk-form4_1762550287.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423825000003/wk-form4_1762550287.xml","form_type":"4"}},{"id":1071421,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2025-08-08T20:54:48.000Z","date":"2025-08-06","kind":"grant","planned":false,"acquired":true,"shares":3696,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":652342,"source":{"system":"sec-edgar","filing":"0001802768-25-000102","document":"wk-form4_1754686485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276825000102/wk-form4_1754686485.xml","form_type":"4"}},{"id":1140545,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class E Ordinary Shares","published_at":"2025-05-20T20:54:54.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1238789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote (1)(2)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares of Royalty Pharma Holdings Ltd (\"RPH\") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the \"Purchase Agreement\") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."}],"balance_after":1238789,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1238789},"source":{"system":"sec-edgar","filing":"0001802768-25-000071","document":"wk-form4_1747774487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276825000071/wk-form4_1747774487.xml","form_type":"4"}},{"id":1153848,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2025-05-09T21:14:15.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":48646,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":648646,"source":{"system":"sec-edgar","filing":"0001802768-25-000035","document":"wk-form4_1746825246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276825000035/wk-form4_1746825246.xml","form_type":"4"}},{"id":1263947,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2025-02-18T22:16:26.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":86641,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001802768-25-000012","document":"wk-form4_1739916980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276825000012/wk-form4_1739916980.xml","form_type":"4"}},{"id":1263946,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2025-02-18T22:16:26.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001802768-25-000012","document":"wk-form4_1739916980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276825000012/wk-form4_1739916980.xml","form_type":"4"}},{"id":1514393,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2024-05-16T21:42:57.000Z","date":"2024-05-13","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":541,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001802768-24-000023","document":"wk-form4_1715895759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276824000023/wk-form4_1715895759.xml","form_type":"4"}},{"id":1514392,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2024-05-16T21:42:57.000Z","date":"2024-05-13","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SCH Investment Partners LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":370000,"source":{"system":"sec-edgar","filing":"0001802768-24-000023","document":"wk-form4_1715895759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000180276824000023/wk-form4_1715895759.xml","form_type":"4"}},{"id":2501015,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T14:10:42.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":1848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":1848},"source":{"system":"sec-edgar","filing":"0001104659-21-142278","document":"tm2133601-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000110465921142278/tm2133601-11_4seq1.xml","form_type":"4"}},{"id":2501014,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T14:10:42.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":92.09,"underlying":"Common Stock","underlying_shares":10267},"source":{"system":"sec-edgar","filing":"0001104659-21-142278","document":"tm2133601-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000110465921142278/tm2133601-11_4seq1.xml","form_type":"4"}},{"id":2501013,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T14:10:42.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":930,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142278","document":"tm2133601-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000110465921142278/tm2133601-11_4seq1.xml","form_type":"4"}},{"id":2772098,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-03-25T23:53:21.000Z","date":"2021-03-23","kind":"sale","acquired":false,"shares":31959,"price":469.859,"value":15016223.781,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RPI US LP Interests were withheld to cover tax withholding obligations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RPI US LP Interests were withheld to cover tax withholding obligations."}],"balance_after":30541,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":319590},"source":{"system":"sec-edgar","filing":"0000950103-21-004602","document":"dp148454_4-hite.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000095010321004602/dp148454_4-hite.xml","form_type":"4"}},{"id":2886140,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T23:38:02.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date"}],"balance_after":1848,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":1848},"source":{"system":"sec-edgar","filing":"0001179110-21-001108","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000117911021001108/edgar.xml","form_type":"4"}},{"id":2886139,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T23:38:02.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":930,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":930,"source":{"system":"sec-edgar","filing":"0001179110-21-001108","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000117911021001108/edgar.xml","form_type":"4"}},{"id":3102127,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"ICAI Interests","published_at":"2020-06-24T01:13:17.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":116100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These ICAI Interests represent a grant of up to 116,100 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These ICAI Interests represent a grant of up to 116,100 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":116100,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":116100},"source":{"system":"sec-edgar","filing":"0000950103-20-012252","document":"dp130800_4-hite.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000095010320012252/dp130800_4-hite.xml","form_type":"4"}},{"id":3102126,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-24T01:13:17.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RPI US LP Interests are subject to one-year vesting, with 100% of the interests vesting on March 22, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":62500,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0000950103-20-012252","document":"dp130800_4-hite.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000095010320012252/dp130800_4-hite.xml","form_type":"4"}},{"id":3102125,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Vice Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-24T01:13:17.000Z","date":"2020-06-18","kind":"purchase","acquired":true,"shares":70000,"price":28,"value":1960000.0,"ownership":{"direct":true},"balance_after":70000,"source":{"system":"sec-edgar","filing":"0000950103-20-012252","document":"dp130800_4-hite.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000095010320012252/dp130800_4-hite.xml","form_type":"4"}},{"id":3120793,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-06-06T00:32:45.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":10267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after the date of grant."}],"balance_after":10267,"derivative":{"exercise_price":92.09,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":10267},"source":{"system":"sec-edgar","filing":"0001179110-20-007062","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000117911020007062/edgar.xml","form_type":"4"}}]}